[script src="./ATLL 2019 ASH_files/adj.php" async=""][/script][script src="./ATLL 2019 ASH_files/osd.js.descarga"][/script][script type="text/javascript" async="" src="./ATLL 2019 ASH_files/analytics.js.descarga"][/script][script type="text/javascript" charset="UTF-8" async="" src="./ATLL 2019 ASH_files/state.js.descarga"][/script][script async="" src="./ATLL 2019 ASH_files/analytics.js.descarga"][/script][script type="text/javascript" async="" src="./ATLL 2019 ASH_files/js"][/script][script type="text/javascript" src="./ATLL 2019 ASH_files/1.txt"][/script][script type="text/javascript" src="./ATLL 2019 ASH_files/1(1).txt"][/script][script type="text/javascript" src="./ATLL 2019 ASH_files/moatframe.js.descarga"][/script] [script async="" src="./ATLL 2019 ASH_files/gtm.js.descarga"][/script][script src="./ATLL 2019 ASH_files/jquery.min.js.descarga" type="text/javascript"][/script] [script]window.jQuery || document.write('[script src="//ash.silverchair-cdn.com/Themes/Silver/app/js/jquery.3.4.1.min.js" type="text/javascript"]\x3C/script>')[/script] [script src="./ATLL 2019 ASH_files/jquery-migrate-3.1.0.min.js.descarga" type="text/javascript"][/script] [script] (function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' }); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-5F4DG3K'); [/script] [script type="text/javascript"] var App = App || {}; App.LoginUserInfo = { isInstLoggedIn: 0, isIndividualLoggedIn: 0 }; App.CurrentSubdomain = 'blood'; App.SiteURL = 'ashpublications.org/blood'; [/script] [script async="async" src="./ATLL 2019 ASH_files/gpt.js.descarga"][/script] [script] var googletag = googletag || {}; googletag.cmd = googletag.cmd || []; googletag.cmd.push(function () { }); [/script] [script src="./ATLL 2019 ASH_files/f.txt" async=""][/script] [script id="altmetric-embed-js" src="./ATLL 2019 ASH_files/altmetric_badges-dae2a658e53c442cd84f4390def938db5569f7911cfa1aa78d8970054ec2f48f.js.descarga"][/script][script src="./ATLL 2019 ASH_files/pubads_impl_2021051701.js.descarga" async=""][/script][script type="text/javascript" src="./ATLL 2019 ASH_files/f(1).txt"][/script][script type="text/javascript" src="./ATLL 2019 ASH_files/f(2).txt"][/script] Skip to Main Content
Advertisement
[script type="text/javascript"] (function() { var hfSiteUrl = document.getElementById('hfSiteURL'); var siteUrl = hfSiteUrl.value; var subdomainIndex = siteUrl.indexOf('/'); hfSiteUrl.value = location.host + (subdomainIndex >= 0 ? siteUrl.substring(subdomainIndex) : ''); })(); [/script]
624.Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies| November 13, 2019
Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)
Luis E Malpica Castillo, MD
1University of North Carolina at Chapel Hill, Chapel Hill, NC
Search for other works by this author on:
Camila Peña, MD
2Hematology Department, Hospital del Salvador, Santiago, Chile
Search for other works by this author on:
Christine Rojas, MD
3Sociedad Chilena de Hematología, Santiago de Chile, Chile
Search for other works by this author on:
Pilar León, MD
4Hospital Carlos Van Buren, Valparaíso, Chile
Search for other works by this author on:
Brady E. Beltrán, MD
5Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres, Lima, Peru
6Departamento de Oncología y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
Search for other works by this author on:
Denisse A. Castro, MD
5Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres, Lima, Peru
6Departamento de Oncología y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
Search for other works by this author on:
Yesenia M. Huerta- Collado, MD ,
Yesenia M. Huerta- Collado, MD
7Department of Oncology and Radiotherapy, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
Search for other works by this author on:
Mimsy Quinones, MD
8Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
Search for other works by this author on:
Sally Rose Paredes, MD
6Departamento de Oncología y Radioterapia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
Search for other works by this author on:
Henry Idrobo, MD
9Facultad de Medicina., Profesor Universidad Del Valle, Cali, Colombia
Search for other works by this author on:
Ivan Perdomo, MD
10Clínica Los Nogales, Bogota, Colombia
Search for other works by this author on:
Virginia Abello, MD
11Hospital de San José. Fundación Universitaria de Ciencias de la Salud (FUCS), Bogota D.C, Colombia
Search for other works by this author on:
Lorena Fiad, MD
12Hematología, Hospital Italiano de La Plata, La Plata, Argentina
Search for other works by this author on:
Victoria Otero, MD
13Sección Hematología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Search for other works by this author on:
Marialejandra Torres Viera, MD ,
Marialejandra Torres Viera, MD
14Universidad Central de Venezuela, Caracas, Venezuela (Bolivarian Republic of)
Search for other works by this author on:
Luis Villela M
15Internal Medicine division/Hematology and blood bank service, Centro Medico Dr. Ignacio Chavez/ISSSTESON/HermosilloSonora, Hermosillo, Mexico
Search for other works by this author on:
Eduardo Sotomayor, MD
16George Washington University Cancer Center, Washington, DC
Search for other works by this author on:
Jorge J Castillo, MD
17Dana-Farber Cancer Institute, Boston, MA
Search for other works by this author on:
Juan Carlos Ramos, MD BS
18Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
Search for other works by this author on:
[script src="./ATLL 2019 ASH_files/widget.js.descarga"][/script]
Blood (2019) 134 (Supplement_1): 4045.
[script] $(document).ready(function () { $('.article-top-widget').on('click', '.ati-toggle-trigger', function () { $(this).find('.icon-general-add, .icon-minus').toggleClass('icon-minus icon-general-add'); $(this).siblings('.ati-toggle-content').toggleClass('hide'); }); // In Chrome, an anchor tag with target="_blank" and a "mailto:" href opens a new tab/window as well as the email client // I suspect this behavior will be corrected in the future // Remove the target="_blank" $('ul.wi-affiliationList').find('a[href^="mailto:"]').each(function () { $(this).removeAttr('target'); }); }); [/script]
Citation
Luis E Malpica Castillo, Camila Peña, Christine Rojas, Pilar León, Brady E. Beltrán, Denisse A. Castro, Yesenia M. Huerta- Collado, Mimsy Quinones, Sally Rose Paredes, Henry Idrobo, Ivan Perdomo, Virginia Abello, Lorena Fiad, Victoria Otero, Marialejandra Torres Viera, Luis Villela M, Eduardo Sotomayor, Jorge J Castillo, Juan Carlos Ramos; Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL). Blood 2019; 134 (Supplement_1): 4045. doi: https://doi.org/10.1182/blood-2019-122976
Download citation file:
toolbar search
[script type="text/javascript"] (function() { var hfSiteUrl = document.getElementById('hfSiteURL'); var siteUrl = hfSiteUrl.value; var subdomainIndex = siteUrl.indexOf('/'); hfSiteUrl.value = location.host + (subdomainIndex >= 0 ? siteUrl.substring(subdomainIndex) : ''); })(); [/script]
Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, peripheral T-cell neoplasm associated with the human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 infects up to 10 million people worldwide and is most endemic in Southwestern Japan, the Caribbean basin, South America and Western Africa. In Latin America, highest prevalence is found in Haiti, Jamaica, Dominican Republic, Brazil and Peru. ATLL has a poor prognosis, with shorter overall survival (OS) relative to other peripheral T-cell lymphomas. Although current prognostic models require extensive radiologic and laboratory investigations, oftentimes they are not readily available in most Latin American countries, hence, a simple prognostic model is useful. We aim to identify and then validate a simple clinical prognostic model for ATLL in the Latin American population by analyzing clinical parameters and only laboratory tests that are widely available across Latin American countries.
Patients and Methods: We retrospectively analyzed patients (pts) diagnosed with ATLL between January 1987 and December 2018. Aggressive ATLL cases were classified according to the Shimoyama criteria into acute (A) and lymphomatous (L). Cox regression modeling was performed on several clinical and laboratory parameters in two independent cohorts: first, a learning cohort (LC) of ATLL pts diagnosed and managed at two tertiary hospitals in Chile and Peru, and then a cohort of ATLL pts from a tertiary hospital in Miami was used to validate the model (validation cohort, VC). OS curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional-hazard regression models were fitted.
Results: A total of 149 pts (A=55, L=94) in the LC, and 101 pts (A=58, L=43) in the VC were identified, with 101 and 94 pts receiving therapy in each cohort, respectively. Clinical features are shown in Table 1. In both cohorts, there was a young (<60 years, LC=51%, VC=64%), and female predominance (LC=52%, VC=61%). Pts in the LC had a better performance status compared to the VC (ECOG ≥2, LC=50% vs. VC=76%). Pts in the VC had advanced stages of disease (stage III/IV, LC=88% vs. VC=97%), and ≥1 extranodal involvement (LC=17% vs. VC=76%) compared to the LC. High LDH, low serum albumin (<3.5 g/dL), bone marrow involvement and anemia (hemoglobin <10 g/dL) were no different in both cohorts. The calculated International Prognostic Index (IPI) and Prognostic Index for T-cell lymphoma (PTI) scores are presented in Table 1. Most pts in the VC had high risk IPI and PIT scores (High risk: IPI LC=21% vs. VC=62%; PIT LC=38% vs. VC=51%) compared to the LC that had more low and low/intermediate IPI and PIT scores (Low risk: IPI LC=13% vs. VC=0%; PIT LC=5% vs. VC=0%; Low/intermediate risk: IPI LC=26% vs. VC=7%; PIT LC=23% vs. VC=16%). The median OS was 6 and 8.4 months in the LC and VC, respectively (Figure 1).
In the univariate and multivariate analysis, ECOG ≥2 and serum albumin <3.5 g/dL were both associated with a worse OS (Table 2). When adjusted to IPI and PIT scores, serum albumin <3.5 g/dL was a negative prognostic factor, independent of IPI score, and a trend in PIT score, in the LC (adjusted for IPI: HR 1.71, 95% CI 1.06-2.75; p=0.03 / PIT: HR 1.56, 95% CI 0.95-2.56; p=0.07), but independent prognostic factor from both, IPI and PIT scores, in the VC (adjusted for IPI: HR 2.45, 95% CI 1.41-4.24; p=0.001 / PIT: HR 2.43, 95% CI 1.44-4.08; p=0.001) (Figure 2). Comparable results were found when investigating by ATLL subtype, with results trending towards significance for OS, IPI and PIT scores in the LC, but then validated in the VC (Figure 3).
Conclusions: To the best of our knowledge, this is the largest retrospective study evaluating the clinical features of HTLV-1 related ATLL and impact on disease outcome in Latin America. We have validated a simple prognostic model in pts with aggressive ATLL. Our results suggest that a serum albumin level of less than 3.5 g/dL is a reliable, and independent prognostic factor for survival in aggressive ATLL. This prognostic model could be used to complement or modify existing and widely used international prognostic indexes for lymphoma. This simple paradigm could be useful in validating treatment outcomes after chemotherapy or highly needed new approaches for ATLL in prospective studies, particularly in developing countries where the absence of sophisticated laboratory and imaging tests hinder treatment decisions.
Disclosures
Peña:Novartis: Other: Congress inscription and flights; Tecnofarma: Other: Congress inscription and flights; Roche: Other: Congress inscription and flights; Biotoscana: Other: Congress inscription and flights; Janssen: Other: Congress inscription and flights; Pfizer: Membership on an entity's Board of Directors or advisory committees. Rojas:Pfizer: Membership on an entity's Board of Directors or advisory committees; ABBVIE: Membership on an entity's Board of Directors or advisory committees; NOVARTIS: Membership on an entity's Board of Directors or advisory committees; ROCHE: Membership on an entity's Board of Directors or advisory committees. Paredes:Tecnofarma: Honoraria. Abello:Takeda: Other: Participation in advisory board meeting. M:Merck-Sharp-Dome: Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Roche-Mexico: Consultancy, Speakers Bureau.
Author notes
*
Asterisk with author names denotes non-ASH members.
© 2019 by The American Society of Hematology
2019
Volume 134, Issue Supplement_1
November 13 2019
Advertisement
[script defer="" async="" src="./ATLL 2019 ASH_files/trendmd.min.js.descarga" data-trendmdconfig="{"journal_id":"55238","element":"#trendmd-suggestions"}"][/script]
Potential Articles of Interest
- Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL)
Idrobo et al., Blood, 2019
- A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL)
Castro et al., Blood, 2019
- Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival
M et al., Blood, 2019
- Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
Hyoeun Shim et al., Annals of Laboratory Medicine
- Establishment of a prognostic scoring model for regional recurrent nasopharyngeal carcinoma after neck dissection
Xiaoyun Li et al., Cancer Biology & Medicine, 2020
- A novel image signature-based radiomics method to achieve precise diagnosis and prognostic stratification of gliomas
Huigao Luo et al., Lab Invest, 2020
I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more
Cited By
Advertisement
Advertisement
- American Society of Hematology
- 2021 L Street NW, Suite 900
- Washington, DC 20036
- TEL +1 202-776-0544
- FAX +1 202-776-0545
Copyright ©2020 by American Society of Hematology
This Feature Is Available To Subscribers Only
[script src="./ATLL 2019 ASH_files/MathJax.js.descarga"][/script] [script src="./ATLL 2019 ASH_files/polyfill.min.js.descarga"][/script] [script type="text/javascript" src="./ATLL 2019 ASH_files/site.min.js.descarga"][/script] [script async="async" src="./ATLL 2019 ASH_files/addthis_widget.js.descarga"][/script] [script async="async" src="./ATLL 2019 ASH_files/chartist.min.js.descarga"][/script] [script async="async" src="https://ashpublications.org/blood/article/134/Supplement_1/4045/424391/Identifying-a-Simple-Clinical-Prognostic-Model-for"][/script] [script type="text/javascript"] $(document).ready(function () { App.SearchAutoComplete.init(["Keywords"]); }); [/script] [script type="text/javascript" src="./ATLL 2019 ASH_files/blood-2019-122976"][/script][script type="text/javascript" id="Cookiebot" src="./ATLL 2019 ASH_files/uc.js.descarga"][/script] [script type="text/javascript" id=""]function CookiebotCallback_OnAccept(){Cookiebot.consent.preferences&&dataLayer.push({event:"cookieconsent_preferences"});Cookiebot.consent.statistics&&dataLayer.push({event:"cookieconsent_statistics"});Cookiebot.consent.marketing&&dataLayer.push({event:"cookieconsent_marketing"})};[/script] [script type="text/javascript" id=""]var CookieManager=function(){function e(a,b){this.cookieVersion="Tue, 01 May 2018 12:22:13 GMT";this.privacyVersion="Mon, 22 April 2019 12:22:13 GMT";this.termsVersion="Tue, 01 May 2018 12:22:13 GMT";this.domain="ashpublications.org";this.unecessaryCookies={preferences:[],statistics:["_gid","_ga"],"marketing:":[]};this.getAcceptanceData(a,function(c){if(document.getElementById("cookie-settings")){var d=document.getElementById("cookie-settings");"true"==c.eu&&(d.style.display="inline")}document.getElementById("opa")&& (this.handlePrivacyTerms(c,a),this.displayPolicyDates());"true"!=c.eu||this.compareDates(c.cookieDate,this.cookieVersion)||a.show();a.onaccept=function(){this.updateAcceptanceData(a,c)}.bind(this);a.ondecline=function(){this.updateAcceptanceData(a,c)}.bind(this)}.bind(this))}e.prototype.updateAcceptanceData=function(a,b){1==this.hasCookie()?this.setCookieConsent(a,b):this.isEU(function(c){this.setCookieConsent(a,this.createAcceptanceData(a,c))}.bind(this))};e.prototype.getAcceptanceData=function(a, b){if(this.hasCookie()){var c=this.getCookie();b(c)}else this.isEU(function(d){c=this.createAcceptanceData(a,d);this.setCookieConsent(a,c);b(c)}.bind(this))};e.prototype.isEU=function(a){var b=new XMLHttpRequest;b.open("GET","//cdn.hematology.org/ip/");b.onreadystatechange=function(){if(4===this.readyState)if(200===this.status){var c=JSON.parse(this.response);"EU"==c.continent_code?(console.log("Response value: "),console.log(c.continent_code),a("true")):a("false")}else console.log("IP lookup failure, EU status undetermined."), a("undetermined")};b.send()};e.prototype.createAcceptanceData=function(a,b){var c=new Date,d=c.toUTCString();switch(b){case "true":var f="true";break;case "false":f="false";break;case "undetermined":f="undetermined"}a=a.consent.necessary?{eu:f,terms:"false",privacy:"false",necessaryCookies:a.consent.necessary.toString(),statisticsCookies:a.consent.statistics.toString(),marketingCookies:a.consent.marketing.toString(),preferenceCookies:a.consent.preferences.toString(),termsDate:d,privacyDate:d,cookieDate:d}: "undetermined"==f?{eu:f,terms:"false",privacy:"false",necessaryCookies:"true",statisticsCookies:"false",marketingCookies:"false",preferenceCookies:"false",termsDate:d,privacyDate:d,cookieDate:d}:{eu:f,terms:"false",privacy:"false",necessaryCookies:"true",statisticsCookies:"true",marketingCookies:"true",preferenceCookies:"true",termsDate:d,privacyDate:d,cookieDate:d};c.setTime(c.getTime()+31536E6);c=c.toUTCString();this.writeAcceptanceCookie(a,c);return a};e.prototype.deleteCookies=function(a){if(this.unecessaryCookies[a])for(var b= 0;b=b)return!0};return e}(),cookieManager=new CookieManager(Cookiebot,dataLayer);[/script][script type="text/javascript" id="" src="./ATLL 2019 ASH_files/gpt.js.descarga"][/script] [script type="text/javascript" id=""]var googletag=googletag||{};googletag.cmd=googletag.cmd||[];googletag.slots=googletag.slots||{}; googletag.cmd.push(function(){googletag.slots["728x90_top"]=googletag.defineSlot("/108367865/BloodJournal.org_New/728x90_Top",[[728,90],[300,50],[320,50]],"dfp-ad-728x90_top").addService(googletag.pubads());googletag.slots["300x250_right"]=googletag.defineSlot("/108367865/BloodJournal.org_New/300x250_Right",[300,250],"dfp-ad-300x250_right").addService(googletag.pubads());googletag.slots["300x250_160x600_300x600_right"]=googletag.defineSlot("/108367865/BloodJournal.org_New/300x250_160x600_300x600_Right", [[300,250],[160,600],[300,600]],"dfp-ad-300x250_160x600_300x600_right").addService(googletag.pubads());googletag.slots.bloodjournal_org_new_728x90_bottom=googletag.defineSlot("/108367865/BloodJournal.org_New/728x90_Bottom",[[728,90],[300,50],[320,50]],"dfp-ad-bloodjournal_org_new_728x90_bottom").addService(googletag.pubads());googletag.slots.interstitial=googletag.defineSlot("/108367865/BloodJournal.org_New/Interstitial",[[1,1],[300,250],[640,480]],"dfp-ad-interstitial").addService(googletag.pubads()); googletag.slots.riserad=googletag.defineSlot("/108367865/BloodJournal.org_New/RiserAd",[[300,50],[320,50],[970,90],[728,90]],"dfp-ad-RiserAd").addService(googletag.pubads());var a=window.location.href;"https://ashpublications.org/blood"==a||"https://ashpublications.org/blood?sso-checked\x3dtrue"==a?(console.log("homepage"),googletag.pubads().setTargeting("page","homepage"),a=a.replace("https://ashpublications.org/blood","")):"https://ashpublications.org/blood/article/134/7/597/260708"==a||"https://ashpublications.org/blood/article/134/7/659/260717"== a||"https://ashpublications.org/blood/article/134/3/304/260710"==a||"https://ashpublications.org/blood/article/134/3/332/260709"==a||"https://ashpublications.org/blood/article/133/25/2664/273892"==a||"https://ashpublications.org/blood/article/133/25/2731/273889"==a||"https://ashpublications.org/blood/article/133/20/2244/273842"==a||"https://ashpublications.org/blood/article/133/20/2222/273854"==a||"https://ashpublications.org/blood/article/133/16/1703/260505"==a||"https://ashpublications.org/blood/article/133/16/1791/260499"== a||"https://ashpublications.org/blood/article/133/12/1386/260460"==a||"https://ashpublications.org/blood/article/133/12/1290/260469"==a||"https://ashpublications.org/blood/article/133/8/857/260604"==a||"https://ashpublications.org/blood/article/133/8/884/260608"==a||"https://ashpublications.org/blood/article/133/3/286/261436"==a||"https://ashpublications.org/blood/article/133/3/215/261440"==a||"https://ashpublications.org/blood/article/132/25/2701/39570"==a||"https://ashpublications.org/blood/article/132/25/2619/39564"== a||"https://ashpublications.org/blood/article/132/20/2143/39510"==a||"https://ashpublications.org/blood/article/132/20/2210/39500"==a||"https://ashpublications.org/blood/article/132/16/1727/39358"==a||"https://ashpublications.org/blood/article/132/16/1714/39362"==a||"https://ashpublications.org/blood/article/132/12/1225/39628"==a||"https://ashpublications.org/blood/article/132/12/1356/39620"==a?(console.log("CME Page"),googletag.pubads().setTargeting("page","CME"),a=a.replace("https://ashpublications.org/blood", "")):"https://ashpublications.org/blood/search-results?f_ArticleTypeDisplayName\x3dMeeting+Report"==a||"https://ashpublications.org/blood/issue/134/Supplement_1"==a||"https://ashpublications.org/blood/issue/132/Supplement%201"==a||"https://ashpublications.org/blood/issue/130/Supplement%201"==a||"https://ashpublications.org/blood/article/128/22"==a||"https://ashpublications.org/blood/article/126/23"==a||"https://ashpublications.org/blood/article/124/21"==a||"https://ashpublications.org/blood/article/106/11"== a||"https://ashpublications.org/blood/article/104/11"==a||"https://ashpublications.org/blood/article/108/11"==a||"https://ashpublications.org/blood/article/110/11"==a||"https://ashpublications.org/blood/article/112/11"==a||"https://ashpublications.org/blood/article/114/22"==a||"https://ashpublications.org/blood/article/116/21"==a||"https://ashpublications.org/blood/article/118/21"==a||"https://ashpublications.org/blood/article/120/11"==a||"https://ashpublications.org/blood/article/120/21"==a||"https://ashpublications.org/blood/article/122/21"== a||a.includes("https://ashpublications.org/blood/issue/134/Supplement_2")||a.includes("https://ashpublications.org/blood/issue/134/Supplement_1")||a.includes("https://ashpublications.org/blood/issue/132/Supplement_1")||a.includes("https://ashpublications.org/blood/issue/130/Supplement_1")||a.includes("https://ashpublications.org/blood/articles/134/Supplement_2")||a.includes("https://ashpublications.org/blood/articles/134/Supplement_1")||a.includes("https://ashpublications.org/blood/articles/132/Supplement_1")|| a.includes("https://ashpublications.org/blood/articles/130/Supplement_1")?(console.log("Annual Meeting Abstract Page"),googletag.pubads().setTargeting("page","AbstractPages"),a=a.replace("https://ashpublications.org/blood","")):"https://ashpublications.org/bloodadvances/search-results?fl_SiteID\x3d1000003\x26page\x3d1\x26f_Subjects\x3dClinical+Guidelines"==a||"https://ashpublications.org/bloodadvances/article/4/2/327/440607/American-Society-of-Hematology-2020-guidelines-for?searchresult\x3d1"==a|| "https://ashpublications.org/bloodadvances/article/4/2/327/440607/American-Society-of-Hematology-2020-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/3/23/3867/429210/American-Society-of-Hematology-2019-guidelines-for?searchresult\x3d1"==a||"https://ashpublications.org/bloodadvances/article/3/23/3867/429210/American-Society-of-Hematology-2019-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/3/23/3898/429211/American-Society-of-Hematology-2019-guidelines-for?searchresult\x3d1"== a||"https://ashpublications.org/bloodadvances/article/3/23/3898/429211/American-Society-of-Hematology-2019-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/3/23/3829/429213/American-Society-of-Hematology-2019-guidelines-for?searchresult\x3d1"==a||"https://ashpublications.org/bloodadvances/article/3/23/3829/429213/American-Society-of-Hematology-2019-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/3/8/1197/260121/Management-of-cancer-associated-anemia-with?searchresult\x3d1"== a||"https://ashpublications.org/bloodadvances/article/3/8/1197/260121/Management-of-cancer-associated-anemia-with?"==a||"https://ashpublications.org/bloodadvances/article/2/22/3292/16093/American-Society-of-Hematology-2018-Guidelines-for?searchresult\x3d1"==a||"https://ashpublications.org/bloodadvances/article/2/22/3292/16093/American-Society-of-Hematology-2018-Guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/2/22/3317/16094/American-Society-of-Hematology-2018-guidelines-for?searchresult\x3d1"== a||"https://ashpublications.org/bloodadvances/article/2/22/3317/16094/American-Society-of-Hematology-2018-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/2/22/3198/16115/American-Society-of-Hematology-2018-guidelines-for?searchresult\x3d1"==a||"https://ashpublications.org/bloodadvances/article/2/22/3198/16115/American-Society-of-Hematology-2018-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/2/22/3257/16107/American-Society-of-Hematology-2018-guidelines-for?searchresult\x3d1"== a||"https://ashpublications.org/bloodadvances/article/2/22/3257/16107/American-Society-of-Hematology-2018-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/2/22/3360/16129/American-Society-of-Hematology-2018-guidelines-for?searchresult\x3d1"==a||"https://ashpublications.org/bloodadvances/article/2/22/3360/16129/American-Society-of-Hematology-2018-guidelines-for"==a||"https://ashpublications.org/bloodadvances/article/2/22/3226/16134/American-Society-of-Hematology-2018-guidelines-for?searchresult\x3d1"== a||"https://ashpublications.org/bloodadvances/article/2/22/3226/16134/American-Society-of-Hematology-2018-guidelines-for"==a||"https://ashpublications.org/blood/issue/134/Supplement_2"==a||"https://ashpublications.org/blood/issue/13"==a||"https://ashpublications.org/blood/issue/136/supplement_1"==a||"https://ashpublications.org/blood/issue/136/Supplement%201"==a?(console.log("BA Guidelines"),googletag.pubads().setTargeting("page","BA_Guidelines"),a=a.replace("https://ashpublications.org/blood","")): "https://ashpublications.org/blood/pages/blood_podcast"==a?(console.log("Podcast Page"),googletag.pubads().setTargeting("page","podcast"),a=a.replace("https://ashpublications.org/blood","")):(console.log("not homepage"),a=a.replace("https://ashpublications.org/blood",""),googletag.pubads().setTargeting("page",a));console.log("URL: "+a);googletag.pubads().enableAsyncRendering();googletag.pubads().enableSingleRequest();googletag.pubads().collapseEmptyDivs();googletag.enableServices()}); googletag.cmd.push(function(){googletag.display("dfp-ad-728x90_top");googletag.display("dfp-ad-300x250_right");googletag.display("dfp-ad-300x250_160x600_300x600_right");googletag.display("dfp-ad-bloodjournal_org_new_728x90_bottom");googletag.display("dfp-ad-interstitial");googletag.display("dfp-ad-RiserAd")});[/script]